Stereologic analysis of histologic parameters of a twice-recurrent ameloblastic fibroma

Monteil, R; Baş, Volkan; Favot, C.; Loubière, R

doi:10.1016/0030-4220(86)90181-7

Cited by 8 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excluding these cases, recurrent or long-standing AFs never transformed into ameloblastoma (2, 86-89). Using a stereologic analysis, Monteil et al (88) concluded that there was a statistically significant increase in the volume of epithelial elements between the original AF and the first recurrence but not between the first and second recurrences.…”

Section: Hybrid Tumor Of Ameloblastoma and Ameloblastic Fibromamentioning

confidence: 99%

So-called Hybrid Odontogenic Tumors: Do they really exist?

et al. 2001

View full text Add to dashboard Cite

Section: Hybrid Tumor Of Ameloblastoma and Ameloblastic Fibromamentioning

confidence: 99%

So-called Hybrid Odontogenic Tumors: Do they really exist?

et al. 2001

View full text Add to dashboard Cite

“…Extirpation or enucleation is generally the treatment of choice, and the prognosis of these tumors is reported to be good (2). However, recurrence (3)(4)(5)(6) and malignant transformation (7-9) of ameloblastic fibroma and related lesions are also reported. A review of the literature of ameloblastic fibrosarcoma indicates that the mesenchymal component shows a great increase in cellularity and is sarcomatous in character (9).…”

mentioning

confidence: 99%

Assessment of growth potential by MIB‐1 immunohistochemistry in ameloblastic fibroma and related lesions of the jaws compared with ameloblastic fibrosarcoma

Sano

Yoshida

Ninomiya

et al. 1998

J Oral Pathology Medicine

View full text Add to dashboard Cite

Sano K, Yoshida S, Ninomiya H, Ikeda H, Ueno K, Sekine J, Iwamoto H, Uehara M, Inokuchi T: Assessment of growth potential by MIB‐1 immunohistochemistry in ameloblastic fibroma and related lesions of the jaws compared with ameloblastic fibrosarcoma. J Oral Pathol Med 1998; 27: 59–63. © Munksgaard, 1998. Specimens from two ameloblastic fibromas (including one recurrent case), two ameloblastic fibro‐odontomas, and one ameloblastic fibrosarcoma were subjected to investigation by MIB‐1 immunohistochemistry in order to elucidate the growth potential of these tumors. MIB‐1 labeling indices in the epithelial component of these tumors ranged from 2.9 to 7.5%, whereas those in the mesenchymal component ranged from 1.5 to 13.5%. Of these, labeling indices in the mesenchymal component of the recurrent ameloblastic fibroma and ameloblastic fibrosarcoma were quite high. These findings suggest that evaluation of growth potential in ameloblastic fibroma and related lesions could be of help in understanding tumor aggressiveness and in selecting appropriate surgical procedures.

show abstract

“…One patient was of particular interest since the tumor recurred twice (45). Another 13 cases of recurrent AF have been reported (24,(57)(58)(59)(60)(61). Although there are no specific clinicopathological findings to predict the recurrence, the mean time between initial treatment and recurrence was 4 years, ranging from 6 months (24) to 23 years (60).…”

Section: Review Of the Literaturementioning

confidence: 99%